Danielle Swaney

University of California, San Francisco
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Coleoid cephalopods exhibit the highest levels of ADAR-mediated RNA editing of any known animal, yet the functional consequences of most recoding events remain largely unknown. We integrate proteomics with biochemical and cellular assays to characterize thousands of recoding events across the Doryteuthis pealeii proteome. Using quantitative and functional mass spectrometry, we show that RNA edit-driven recoding reshapes the cellular proteome to alter protein stability, subcellular localization, post-translational modifications, and enzymatic activity. —Recoding can regulate post-translational modifications through their creation or ablation, and this has direct effects on protein function and protein-protein interactions. Recoding of the E3 ligase MARCHF5 drives widespread changes in substrate ubiquitylation and perturbs mitochondrial homeostasis, illustrating how RNA editing can influence organelle function. These data provide the first proteome-scale view of how extensive RNA recoding diversifies protein function in coleoid cephalopods and offers a new framework for understanding how RNA-level plasticity shapes protein function and cellular physiology.

Year:

2025

Open Reading Frame 9b (Orf9b), an accessory protein of SARS-CoV and –2, is involved in innate immune suppression through its binding to the mitochondrial receptor Translocase of Outer Membrane 70 (Tom70). Previous structural studies of Orf9b in isolation revealed a β-sheet-rich homodimer; however, structures of Orf9b in complex with Tom70 revealed a monomeric helical fold. Here, we developed a biophysical model that quantifies how Orf9b switches between these conformations and binds to Tom70, a requirement for suppressing the type 1 interferon response. We used this model to characterize the effect of lipid binding and mutations in variants of concern to the Orf9b:Tom70 equilibrium. We found that the binding of a lipid to the Orf9b homodimer biases the Orf9b monomer:dimer equilibrium towards the dimer by reducing the dimer dissociation rate ~100 fold. We also found that mutations in variants of concern can alter different microscopic rate constants without significantly affecting binding to Tom70. Together, our results highlight how perturbations to different steps in these coupled equilibria can affect the apparent affinity of Orf9b to Tom70, with potential downstream implications for interferon signaling in coronavirus infection.

Year:

2025

Virus-host competition drives evolution of diverse antivirus defenses, but how they co-operate in wild bacteria and how bacteriophages circumvent host immunity remains poorly understood. Here, using a functional screening platform to systematically explore the functions of phage accessory genes, we describe how cell-surface barriers can obscure the phenotypes of intracellular defenses in E. coli isolates. LPS modification emerged as a major theme, with the discovery of several small phage proteins that modify specific O-antigen structures, removing barriers to phage adsorption. Bypassing O-antigen in wild E. coli strains revealed another layer of defense: Type IV restriction endonucleases (RE) that target modified DNA of T-even phages (T2, T4, T6). We further show how injected proteins Ip2 and Ip3 of T4 inhibit distinct subtypes of these Type IV REs. Extensive variability in Type IV REs likely drives the emergence of subtype-specific inhibitors through multiple rounds of adaptation and counter-adaptation.

Year:

2025

Open Reading Frame 9b (Orf9b), an accessory protein of SARS-CoV and -2, is involved in innate immune suppression through its binding to the mitochondrial receptor Translocase of Outer Membrane 70 (Tom70). Previous structural studies of Orf9b in isolation revealed a β-sheet-rich homodimer, however, structures of Orf9b in complex with Tom70 revealed a monomeric helical fold. Here, we developed a biophysical model that quantifies how Orf9b switches between these conformations and binds to Tom70, a requirement for suppressing the type 1 interferon response. We used this model to characterize the effect of lipid binding and mutations in variants of concern to the Orf9b:Tom70 equilibrium. We found that the binding of a lipid to the Orf9b homodimer biases the Orf9b monomer:dimer equilibrium towards the dimer by reducing the dimer dissociation rate ∼100-fold. We also found that mutations in variants of concern can alter different microscopic rate constants without significantly affecting binding to Tom70. Together our results highlight how perturbations to different steps in these coupled equilibria can affect the apparent affinity of Orf9b to Tom70, with potential downstream implications for interferon signaling in coronavirus infection.

Year:

2025

Coronaviruses, including SARS-CoV-2, can cause severe disease in humans, whereas reservoir hosts like Rhinolophus bats remain asymptomatic. To investigate how host-specific protein-protein interactions (PPIs) influence infection, we generated comparative PPI maps for SARS-CoV-2 and its bat-origin relative RaTG13 using affinity purification-mass spectrometry (AP-MS) in human and Rhinolophus ferrumequinum (RFe) bat cells. This approach identified both conserved and virus- and host-specific interactions that regulate infection dynamics. Notably, SARS-CoV-2 required a non-synonymous mutation in nucleocapsid to replicate in bat cells expressing human ACE2 and TMPRSS2. Analysis of the viral protein Orf9b revealed differential interactions with mitochondrial proteins Tom70 and MTARC2. A single residue difference in Orf9b between SARS-CoV-2 and RaTG13 functions as a molecular switch, weakening Tom70 binding and immune evasion in human cells while enhancing interaction with the bat-specific restriction factor MTARC2. These findings demonstrate how a single-residue substitution can reshape virus-host interactions and contribute to immune evasion and host adaptation.

Year:

2025

Selective inhibition of mRNA translation is a promising strategy for modulating the activity of disease-associated genes, yet achieving both high potency and specificity remains challenging. Rocaglamide A (RocA), a molecular glue, inhibits translation by clamping eIF4A onto polypurine motifs found in many transcripts, thereby limiting RocA’s specificity. Here, we developed RocASO, a chemical conjugate that links RocA to an antisense oligonucleotide (ASO) capable of base-pairing with defined mRNA sequences, thus directing RocA’s clamping mechanism to chosen targets and enhancing overall potency and specificity. We show that RocASOs are compatible with various types of ASO modalities, including gapmers that induce the degradation of target RNAs. RocASOs were designed to effectively knock down endogenous genes ( PTGES3 , HSPA1B ) and SARS-CoV-2 viral RNA, the latter conferring potent antiviral activity in cells. These findings establish RocASO as a versatile platform for programmable translational inhibition with therapeutic potential.

Year:

2025

Open Reading Frame 9b (Orf9b), an accessory protein of SARS-CoV and –2, is involved in innate immune suppression through its binding to the mitochondrial receptor Translocase of Outer Membrane 70 (Tom70). Previous structural studies of Orf9b in isolation revealed a β-sheet-rich homodimer, however, structures of Orf9b in complex with Tom70 revealed a monomeric helical fold. Here, we developed a biophysical model that quantifies how Orf9b switches between these conformations and binds to Tom70, a requirement for suppressing the type 1 interferon response. We used this model to characterize the effect of lipid binding and mutations in variants of concern to the Orf9b:Tom70 equilibrium. We found that the binding of a lipid to the Orf9b homodimer biases the Orf9b monomer:dimer equilibrium towards the dimer by reducing the dimer dissociation rate ∼100-fold. We also found that mutations in variants of concern can alter different microscopic rate constants without significantly affecting binding to Tom70. Together our results highlight how perturbations to different steps in these coupled equilibria can affect the apparent affinity of Orf9b to Tom70, with potential downstream implications for interferon signaling in coronavirus infection.

Year:

2025

Open Reading Frame 9b (Orf9b), an accessory protein of SARS-CoV and -2, is involved in innate immune suppression through its binding to the mitochondrial receptor Translocase of Outer Membrane 70 (Tom70). Previous structural studies of Orf9b in isolation revealed a β-sheet-rich homodimer, however, structures of Orf9b in complex with Tom70 revealed a monomeric helical fold. Here, we developed a biophysical model that quantifies how Orf9b switches between these conformations and binds to Tom70, a requirement for suppressing the type 1 interferon response. We used this model to characterize the effect of lipid binding and mutations in variants of concern to the Orf9b:Tom70 equilibrium. We found that the binding of a lipid to the Orf9b homodimer biases the Orf9b monomer:dimer equilibrium towards the dimer by reducing the dimer dissociation rate ∼100-fold. We also found that mutations in variants of concern can alter different microscopic rate constants without significantly affecting binding to Tom70. Together our results highlight how perturbations to different steps in these coupled equilibria can affect the apparent affinity of Orf9b to Tom70, with potential downstream implications for interferon signaling in coronavirus infection.

Year:

2025

Hepatitis B virus (HBV) infections promote liver cancer initiation by inducing inflammation and cellular stress. Despite a primarily indirect effect on oncogenesis, HBV is associated with a recurrent genomic phenotype in hepatocellular carcinoma (HCC), suggesting that it impacts the biology of established HCC. Characterization of the interaction of HBV with host proteins and the mechanistic contributions of HBV to HCC initiation and maintenance could provide insights into HCC biology and uncover therapeutic vulnerabilities. In this study, we used affinity purification mass spectrometry to comprehensively map a network of 145 physical interactions between HBV and human proteins in HCC. A subset of the host factors targeted by HBV proteins were preferentially mutated in non–HBV-associated HCC, suggesting that their interaction with HBV influences HCC biology. HBV interacted with proteins involved in mRNA splicing, mitogenic signaling, and DNA repair, with the latter set interacting with the HBV oncoprotein X (HBx). HBx remodeled the PP2A phosphatase complex by excluding striatin regulatory subunits from the PP2A holoenzyme, and the HBx effects on PP2A caused Hippo kinase activation. In parallel, HBx activated mTOR complex 2, which can prevent YAP degradation. mTOR complex 2–mediated upregulation of YAP was observed in human HCC specimens and mouse HCC models and could be targeted with mTOR kinase inhibitors. Thus, HBV interaction with host proteins rewires HCC signaling rather than directly activating mitogenic pathways, providing an alternative paradigm for the cellular effects of a tumor-promoting virus. Significance: Integrative proteomic and genomic analysis of HBV/host interactions illuminated modifiers of hepatocellular carcinoma behavior and key signaling mechanisms in advanced disease, which suggested that HBV may have therapeutically actionable effects.

Year:

2025

The main protease (M Pro ) of SARS-CoV-2 is crucial for viral replication and is the target of nirmatrelvir (the active ingredient of Paxlovid) and ensitrelvir. The identification of new agents with differentiated pharmacokinetic and drug resistance profiles will increase therapeutic options for COVID-19 patients and bolster pandemic preparedness generally. Starting with a lead-like dihydrouracil chemotype from a large-library docking campaign, we improved M Pro inhibition >1,000-fold by engaging additional sub-sites in the M Pro active site, most notably by employing a latent propargyl electrophile to engage the catalytic Cys145. Advanced leads from this series, including AVI-4516 and AVI-4773 show pan-coronavirus antiviral activity in cells, very low clearance in mice, and for AVI-4773 a rapid reduction in viral titers more than a million-fold after just three doses, more rapidly and effectively than the approved drugs, nirmatrelvir and ensitrelvir. Both AVI-4516 and AVI-477 3 are well distributed in mouse tissues, including brain, where concentrations ten or fifteen-thousand times the EC 90 , respectively, are observed eight hours after an oral dose. As exemplar of the series, AVI-4516 shows minimal inhibition of major CYP isoforms and human cysteine and serine proteases, likely due to its latent–electrophilic warhead. AVI-4516 also exhibits synergy in cellular infection models in combination with the RdRp inhibitor molnupiravir, while related analogs strongly inhibit nirmatrelvir-resistant M Pro mutant virus in cells. The in vivo and antiviral properties of this new chemotype are differentiated from existing clinical and pre-clinical M Pro inhibitors, and will advance new therapeutic development against emerging SARS-CoV-2 variants and other coronaviruses. One sentence summary This manuscript describes the discovery of a new class of potent inhibitors of the SARS-CoV-2 major proteases (M Pro ) with a unique mechanism of inhibition, pan coronaviral activity in cellulo , exquisite selectivity vs. the human proteome, and exceptional in vivo efficacy in SARS-CoV-2 infection models that surpasses that of currently approved agents.

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (47)

R. Jeffrey Neitz

Professor

University of California, San Francisco

UNITED STATES
View details

Brian K. Shoichet

University of California, San Francisco

UNITED STATES
View details

David Agard

Professor of Biochemistry & Biophysics

University of California, San Francisco

UNITED STATES
View details

Andrea Fossati

Professor

Vita-Salute San Raffaele University

ITALY
View details

Irene Chen

Gladstone Institutes

UNITED STATES
View details

Davide Ruggero

Professor

University of California

UNITED STATES
View details

Manon Eckhardt

Gladstone Institutes

UNITED STATES
View details

Joseph Bondy-Denomy

Professor

University of California

UNITED STATES
View details

Nevan Krogan

Professor

University of California, San Francisco

UNITED STATES
View details

Luis Martinez-Sobrido

Professor

Texas Biomedical Research Institute

UNITED STATES
View details

Michael A. Matthay

University of California

UNITED STATES
View details

Takaya Togo

Institute of Science Tokyo

JAPAN
View details

Hector Aguilar-Carreno

Associate Professor of Virology

Cornell University

UNITED STATES
View details

Nolwenn Jouvenet

Group leader

Institut Pasteur

FRANCE
View details

Michelle R. Arkin

Professor and Department Chair

University of California

UNITED STATES
View details

Paola Bisignano

Research Associate Professor

Vanderbilt University School of Medicine

UNITED STATES
View details

Fabian Theis

Director of the Institute of Computational Biology and Professor

Technical University of Munich

GERMANY
View details

Alan Ashworth

University of California, San Francisco

UNITED STATES
View details

Taha Taha

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Calixto-Hope G Lucas

Johns Hopkins University School of Medicine

UNITED STATES
View details

Monita Muralidharan

University of California, San Francisco

UNITED STATES
View details

Ignacia Echeverria

Assistant Adjunct Professor

University of California, San Francisco

UNITED STATES
View details

Benjamin Polacco

University of California, San Francisco

UNITED STATES
View details

Duygu Kuzuoglu Ozturk

Assistant Prof

Sabancı University

TURKEY
View details

Harmit Malik

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Adam Renslo

Professor

University of California, San Francisco

UNITED STATES
View details

Harm van Bakel

Associate Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Trey Ideker

Professor

University of California, San Diego

UNITED STATES
View details

Danielle Jorgens

Director

University of California, Berkeley

UNITED STATES
View details

John D. Gordan

University of California

UNITED STATES
View details

Pornparn Kongpracha

University of California, San Francisco

UNITED STATES
View details

Xin Chen

University of Hawai'i Cancer Center

UNITED STATES
View details

Michael Grabe

Professor

UCSF Cardiovascular Research Institute

UNITED STATES
View details

Hagai Tzachi

Tel Aviv University

ISRAEL
View details

Charles S. Craik

Professor

University of California, San Francisco

UNITED STATES
View details

David R Raleigh

University of California, San Francisco

UNITED STATES
View details

Melanie Ott

Professor

University of California, San Francisco

UNITED STATES
View details

Chengjin Ye

Texas Biomedical Research Institute

UNITED STATES
View details

Huadong Chen

University of California, San Francisco

UNITED STATES
View details

Joanna Kovalski

Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Javier Juste

Assistant Professor

-

SPAIN
View details

Kevan Shokat

Professor

UCSF Medical Center

UNITED STATES
View details

Jennifer Hayashi

Assistant Professor

Vassar College

UNITED STATES
View details

Janet Young

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

James Fraser

Professor

University of California, San Francisco

UNITED STATES
View details

Harish Vasudevan

University of California, San Francisco

UNITED STATES
View details

Judd Hultquist

Assistant Professor

Northwestern University

UNITED STATES
View details